Biomarkers for prostate cancer and methods for their detection
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsJeffrey Gildersleeve, Christopher Campbell, Oyindasola Oyelaran, James Gulley, Jeffrey Schlom
Life of this patent
Estimating the term…
Abstract
The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.
Claims26
A method for predicting the clinical response to a viral vector-based vaccine in a patient and treating prostate cancer in the patient, the method comprising:
- obtaining a serum sample from a patient having prostate cancer who has not been previously administered the viral vector-based vaccine, wherein the viral vector-based vaccine comprises a primer vaccination of a recombinant vaccinia virus encoding prostate specific antigen (PSA), B7.1, LFA-3, and ICAM-1;
- assaying the serum sample to determine the levels of antibodies in the patient to at least one glycan and/or glycoprotein antigen selected from the group consisting of Forssman antigen and GalNAcα1-3(Fucα1-2)Galβ-(BG-A);
- comparing the determined levels of antibodies to the at least one glycan and/or glycoprotein antigen to a control and predicting the clinical response to the viral vector-based vaccine in the patient;
- and
- treating the prostate cancer by administering the viral vector-based vaccine to the patient.
A method for determining the immune response to a viral vector-based vaccine in a patient and treating prostate cancer in the patient, the method comprising:
- obtaining a first serum sample from a patient having prostate cancer who has not been previously administered the viral vector-based vaccine, wherein the viral vector-based vaccine comprises a primer vaccination of a recombinant vaccinia virus encoding prostate specific antigen (PSA), B7.1, LFA-3, and ICAM-1;
- obtaining a second serum sample from the patient after administration of the viral vector-based vaccine,
- assaying the first and second serum samples to determine the first and second levels of antibodies, respectively, to at least one glycan and/or glycoprotein antigen selected from the group consisting of Forssman antigen and GalNAcα1-3(Fucα1-2)Galβ-(BG-A);
- comparing the determined first and second levels of antibodies to the at least one glycan and/or glycoprotein antigen and determining the immune response to the viral vector-based vaccine in the patient;
- and
- treating the prostate cancer in the patient by administering a booster vaccine comprising a recombinant fowlpox virus encoding PSA, B7.1, LFA-3, and ICAM-1 to the patient.
A method for predicting the clinical response to a viral vector-based vaccine in a patient and treating prostate cancer in the patient, the method comprising:
- administering the viral vector-based vaccine to the patient, wherein the viral vector-based vaccine comprises a primer vaccination of a recombinant vaccinia virus encoding prostate specific antigen (PSA), B7.1, LFA-3, and ICAM-1;
- obtaining a serum sample from the patient to which the vaccine was administered;
- assaying the serum sample to determine the levels of antibodies in the patient to at least one glycan and/or glycoprotein antigen selected from the group consisting of Forssman antigen and GalNAcα1-3 (Fucα1-2)Galβ-(BG-A);
- comparing the determined levels of antibodies to the at least one glycan and/or glycoprotein antigen to a control and predicting the clinical response to the viral vector-based vaccine in the patient;
- and
- treating the prostate cancer in the patient by administering a booster vaccine comprising a recombinant fowlpox virus encoding PSA, B7.1, LFA-3, and ICAM-1 to the patient.
A method for predicting the clinical response to a viral vector-based vaccine in a patient and treating prostate cancer in the patient, the method comprising:
- obtaining a first serum sample from a patient having prostate cancer,
- assaying the first serum sample to determine the first levels of antibodies in the patient to GalNAcα1-3(Fucα1-2)Galβ-(BG-A) and Forssman antigen;
- administering a primer vaccination of a recombinant vaccinia virus encoding prostate specific antigen (PSA), B7.1, LFA-3, and ICAM-1 to the patient;
- obtaining a second serum sample from the patient after the primer vaccination was administered;
- assaying the second serum sample to determine the second levels of antibodies in the patient to the Forssman antigen;
- comparing the first and second levels of antibodies to the Forssman antigen and predicting the clinical response to the viral vector-based vaccine in the patient;
- and
- treating the prostate cancer in the patient by administering one or more booster vaccines comprising recombinant fowlpox virus encoding PSA, B7.1, LFA-3, and ICAM-1 to the patient.
Dependencies are inferred from the claim text.